Brainsway (BWAY) Stock Price, News & Analysis

Company Overview

Brainsway Ltd is a medical device company specializing in non-invasive neuromodulation therapies. Publicly traded on the NASDAQ under the symbol BWAY, the company develops and commercializes deep transcranial magnetic stimulation (Deep TMS) systems designed to treat a range of neuropsychiatric and neurological disorders. Brainsway’s technology aims to offer an alternative or complement to traditional pharmacological therapies by targeting precise brain regions with its patented coil designs.

The company’s flagship Deep TMS platform utilizes proprietary H-coil arrays engineered to reach deeper cortical structures than conventional TMS devices. Brainsway has secured regulatory clearances in key markets, including U.S. Food and Drug Administration approvals for treatment-resistant major depressive disorder, obsessive-compulsive disorder, and smoking cessation. In addition to cleared indications, the company is pursuing clinical studies in areas such as migraine and substance use disorders to expand its therapeutic portfolio.

Founded in 2003 and headquartered in Jerusalem, Israel, Brainsway operates through subsidiaries and distribution partners across North America, Europe and the Asia-Pacific region. The company maintains a sales and support presence in the United States, including a facility in North Carolina, and collaborates with academic medical centers and independent clinics to facilitate training, research and patient access.

Brainsway’s leadership team brings together experts in neuroscience, clinical medicine and medical technology commercialization. The company continues to invest in research collaborations and real-world evidence initiatives aimed at demonstrating the long-term safety, efficacy and health-economic value of its Deep TMS solutions.

Key Stats

• Today's Range: $15.94 to $16.47
• 50-Day Range: $11.47 to $16.89
• 52-Week Range: $7.84 to $17.00
• Volume: 35,236 shs
• Average Volume: 56,688 shs
• Market Capitalization: $303.16 million
• P/E Ratio: 61.69
• Dividend Yield: N/A
• Price Target: $18.00
• Consensus Rating: Buy

Brainsway Stock Analysis - MarketRank™

Brainsway scored higher than 59% of companies evaluated by MarketBeat, and ranked 519th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.8 / 5
• Analyst Rating: Buy

Consensus Rating

Brainsway has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Brainsway has a consensus price target of $18.00, representing about 11.8% upside from its current price of $16.10.

Amount of Analyst Coverage

Brainsway has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 100.00%

Earnings Growth

Earnings for Brainsway are expected to grow by 100.00% in the coming year, from $0.08 to $0.16 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Brainsway is 61.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 281.82.

Price to Earnings Ratio vs. Sector

The P/E ratio of Brainsway is 61.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 76.75.

Price to Book Value per Share Ratio

Brainsway has a P/B Ratio of 4.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.25% of the float of Brainsway has been sold short.

Short Interest Ratio / Days to Cover

Brainsway has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Brainsway has recently increased by 191.78%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Brainsway does not currently pay a dividend.

Dividend Growth

Brainsway does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.25% of the float of Brainsway has been sold short.

Short Interest Ratio / Days to Cover

Brainsway has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Brainsway has recently increased by 191.78%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.20

News Sentiment

Brainsway has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 7 news articles for Brainsway this week, compared to 2 articles on an average week.

MarketBeat Follows

Only 1 people have added Brainsway to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Brainsway insiders have not sold or bought any company stock.

Percentage Held by Insiders

19.00% of the stock of Brainsway is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 30.11% of the stock of Brainsway is held by institutions.

BWAY Stock Analysis - Frequently Asked Questions

How have BWAY shares performed this year?

Brainsway's stock was trading at $9.43 on January 1st, 2025. Since then, BWAY shares have increased by 70.7% and is now trading at $16.0950.

How were Brainsway's earnings last quarter?

Brainsway Ltd. Sponsored ADR (NASDAQ:BWAY) released its quarterly earnings data on Wednesday, August, 13th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.07 by $0.03. The firm earned $12.63 million during the quarter, compared to the consensus estimate of $12.34 million. Brainsway had a trailing twelve-month return on equity of 8.97% and a net margin of 11.60%.
Read the conference call transcript.

When did Brainsway IPO?

Brainsway (BWAY) raised $30 million in an initial public offering on Wednesday, April 17th 2019. The company issued 2,500,000 shares at $11.94 per share. Cantor acted as the underwriter for the IPO.

Who are Brainsway's major shareholders?

Top institutional investors of Brainsway include Phoenix Financial Ltd. (1.92%), Acadian Asset Management LLC (1.77%), ARK Investment Management LLC (1.06%) and Huntleigh Advisors Inc. (0.41%).

How do I buy shares of Brainsway?

Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Brainsway own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Brainsway investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), Jabil (JBL), e.l.f. Beauty (ELF), Novo Nordisk A/S (NVO) and AppLovin (APP).

Company Calendar

• Last Earnings: 8/13/2025
• Today: 9/18/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:BWAY
• CIK: 1505065
• Web: www.brainsway.com
• Phone: (722) 582-4030
• Fax: N/A
• Employees: 120
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Brainsway: $18.00
• High Price Target: $19.00
• Low Price Target: $17.00
• Potential Upside/Downside: +11.6%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.26
• Trailing P/E Ratio: 62.06
• Forward P/E Ratio: 201.69
• P/E Growth: N/A
• Net Income: $2.92 million
• Net Margins: 11.60%
• Pretax Margin: 12.66%
• Return on Equity: 8.97%
• Return on Assets: 5.65%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.51
• Quick Ratio: 3.34

Sales & Book Value

• Annual Sales: $41.02 million
• Price / Sales: 7.43
• Cash Flow: $0.24 per share
• Price / Cash Flow: 67.73
• Book Value: $3.31 per share
• Price / Book: 4.87

Miscellaneous

• Outstanding Shares: 18,900,000
• Free Float: 15,311,000
• Market Cap: $304.95 million
• Optionable: Not Optionable
• Beta: 1.34